文献速递术前评估与围术期医学

帕洛诺司琼预防日间手术后出院后恶心呕吐:前瞻性随机双盲安慰剂对照试验

Palonosetron as prophylaxis for post-discharge nausea and vomiting: a prospective, randomised, double-blind, placebo-controlled trial in ambulatory surgery.
PubMed 文献 · Br J Anaesth · 2023-05-26

该前瞻性随机双盲安慰剂对照试验纳入170例日间全麻手术且出院后恶心呕吐(PDNV)高风险患者,出院前分别给予帕洛诺司琼75 μg静脉注射或生理盐水。主要结局为术后第2天无恶心呕吐且未用解救药物的完全缓解率,两组分别为48%和36%,差异无统计学意义;术后第1天和第2天PDNV发生率帕洛诺司琼组显著低于安慰剂组。

要点

  • 帕洛诺司琼未降低术后第2天总体完全缓解率(48% vs 36%,P=0.131)。
  • 术后第1天PDNV发生率帕洛诺司琼组显著低于安慰剂组(18% vs 34%,P=0.033)。
  • 术后第2天PDNV发生率帕洛诺司琼组显著低于安慰剂组(9% vs 27%,P=0.007)。

核心结论

  • 与安慰剂相比,帕洛诺司琼未降低术后第2天总体PDNV发生率。
  • 帕洛诺司琼组术后第1天和第2天PDNV发生率较低,需进一步研究。

研究设计与样本

  • 前瞻性、随机、双盲、安慰剂对照试验。
  • 170例日间全麻手术且PDNV高风险患者,随机接受帕洛诺司琼75 μg静脉注射(n=84)或生理盐水(n=86)。
  • 出院前给药,术后3天采用患者问卷测量结局。

主要发现

  • 术后第2天完全缓解率帕洛诺司琼组48%(n=32),安慰剂组36%(n=25),比值比1.69(95%CI 0.85-3.37),P=0.131。
  • 手术当天PDNV发生率两组分别为47%和56%,P=0.31。
  • 术后第1天PDNV发生率帕洛诺司琼组18%,安慰剂组34%,P=0.033。
  • 术后第2天PDNV发生率帕洛诺司琼组9%,安慰剂组27%,P=0.007。
  • 术后第3天PDNV发生率两组分别为15%和13%,P=0.700。

临床怎么用

  • 帕洛诺司琼75 μg静脉注射于出院前给药,未显著改善术后第2天总体完全缓解率。
  • 术后第1天和第2天PDNV发生率降低提示可能获益,但需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 25% of ambulatory surgery patients experience post-discharge nausea and vomiting (PDNV). We aimed to investigate whether palonosetron, a long-acting anti-emetic, decreases the incidence of PDNV in high-risk patients. METHODS: In this prospective, randomised, double-blind, placebo-controlled trial, 170 male and female patients undergoing ambulatory surgery under general anaesthesia, with a high predicted risk for PDNV, were randomised to receive either palonosetron 75 μg i.v. (n=84) or normal saline (n=86) before discharge. During the first 3 postoperative days (PODs), we measured outcomes using a patient questionnaire. The primary outcome was the incidence of a complete response (no nausea, vomiting, or use of rescue medication) until POD 2. Secondary outcomes included the incidence of PDNV each day until POD 3. RESULTS: The incidence of a complete response until POD 2 was 48% (n=32) in the palonosetron group and 36% (n=25) in the placebo group (odds ratio 1.69 [95% confidence interval: 0.85-3.37]; P=0.131). No significant difference in the incidence of PDNV was observed between the two groups on the day of surgery (47% vs 56%; P=0.31). Significant differences in the incidence of PDNV were found on POD 1 (18% vs 34%; P=0.033) and POD 2 (9% vs 27%; P=0.007). No differences were observed on POD 3 (15% vs 13%; P=0.700). CONCLUSIONS: Compared with placebo, palonosetron did not reduce the overall incidence of post-discharge nausea and vomiting up to postoperative day 2. The lower incidence of post-discharge nausea and vomiting on poatoperative days 1 and 2 in the palonosetron group requires further investigation. CLINICAL TRIAL REGISTRATION: EudraCT 2015-003956-32.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Moraitis A, Myrberg T, Hultin M, et al. Palonosetron as prophylaxis for post-discharge nausea and vomiting: a prospective, randomised, double-blind, placebo-controlled trial in ambulatory surgery. Br J Anaesth. 2023. PMID: 37246062. doi:10.1016/j.bja.2023.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。